SCHEMBL444029

SCHEMBL444029

N#CCc1ccc(Cl)cc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.49
HTR2A P28223 4/20 0.39
TP53 P04637 1/20 0.39
HTR1A P08908 1/20 0.39
HTR7 P34969 1/20 0.39
HTR6 P50406 1/20 0.39
CXCR3 P49682 3/20 0.37
SLC6A4 P31645 4/20 0.36
KCNH2 Q12809 4/20 0.36
IDO1 P14902 2/20 0.36
SLC6A2 P23975 1/20 0.36
FFAR1 O14842 2/20 0.36
FFAR4 Q5NUL3 2/20 0.36
TSPO P30536 1/20 0.36
DRD3 P35462 1/20 0.36
GRM2 Q14416 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30317077 1.00 CYP2A6 (0.49) CYP2A6HTR2ATP53HTR1AHTR7
SCHEMBL836823 0.86 CYP2A6 (0.50) CYP2A6HTR2ASLC6A4KCNH2IDO1
SCHEMBL2761139 0.81 MAOB (0.44) CYP2A6ALDH1A1
SCHEMBL11339655 0.81 CYP2A6 (0.53) CYP2A6IDO1CYP1A2CYP3A4CYP2C9
SCHEMBL16992744 0.81 FFAR1 (0.42) CYP2A6HTR2ATP53HTR1AHTR7
SCHEMBL5546270 0.80 CYP3A4 (0.39) HTR2ATP53HTR1AHTR7HTR6
SCHEMBL3075954 0.80 CYP2A6 (0.49) CYP2A6IDO1SLC6A2CYP1A2CYP3A4
SCHEMBL548158 0.79 IDO1 (0.48) HTR2ASLC6A4KCNH2IDO1FFAR1
SCHEMBL549082 0.79 CYP1A2 (0.57) CYP2A6TP53IDO1CYP1A2CYP3A4
SCHEMBL29700948 0.79 IDO1 (0.48) HTR2ASLC6A4KCNH2IDO1FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102239158-A Method for preparing a spiroindoline and a precursor thereof GLAXO GROUP LTD 2011-11-09 CN claimed
EP-2370423-A1 METHOD FOR PREPARING A SPIROINDOLINE AND A PRECURSOR THEREOF Glaxo Group Limited (GB) 2011-10-05 EP claimed
US-20110230660-A1 METHOD FOR PREPARING A SPIROINDOLINE AND A PRECURSOR THEREOF Method for Preparing a Spiroindoline 2011-09-22 US claimed
WO-2010065704-A1 METHOD FOR PREPARING A SPIROINDOLINE AND A PRECURSOR THEREOF GLAXO GROUP LIMITED (GB) 2010-06-10 WO claimed
US-12552783-B2 Modulators of proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-02-17 US disclosed
US-12528785-B2 MDM2 degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-01-20 US disclosed
EP-3860654-B1 PHOTORESPONSIVE NUTLIN DERIVATIVES AND USES THEREOF UNIV GRONINGEN (NL) 2025-06-25 EP disclosed
CN-116283701-B Compounds having the structure 4- (substituted aminomethyl) -5-neopentyl-N-substituted pyrrolidine-2-carboxamide 中国科学院上海药物研究所 2025-04-22 CN disclosed
US-20240424110-A1 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-12-26 US disclosed
US-12054474-B2 Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-08-06 US disclosed
CN-118047784-A Small molecule compound with substituted phenyl spiro [ indoline-3, 3' -pyrrolidine ] structure 中国科学院上海药物研究所 2024-05-17 CN disclosed
US-11981664-B2 Photoresponsive nutlin derivatives and uses thereof RIJKSUNIVERSITEIT GRONINGEN (NL) 2024-05-14 US disclosed
US-20050234097-A1 Compounds useful for the treatment of diseases PFIZER INC 2005-10-20 US disclosed
WO-2005090287-A2 PHENYLETHANOLAMINE DERIVATIVES AS BETA-2 AGONISTS PFIZER LIMITED (GB) 2005-09-29 WO disclosed
US-6242634-B1 OF HERBICIDES, HALOPHENYL COMPOUNDS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-06-05 US disclosed
US-6100257-A 2-HALOALKYL,3-(HALOALKYL, ALKENYL, OR ALKYNYL),5-(SUBSTITUTED PHENYL OR HETEROCYCLE),6-ALKYL-PYRIMIDIN-4-ONE COMPOUNDS OF GIVEN STRUCTURE; USE AS HERBICIDES SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2000-08-08 US disclosed
CN-1198742-A Pyrimidin-4-one derivatives, their use as herbicides, intermediates for their production and process for producing these compounds SUMITOMO CHEMICAL CO (JP) 1998-11-11 CN disclosed
EP-0850229-A1 PYRIMIDIN-4-ONE DERIVATIVES, THEIR USE AS HERBICIDES, INTERMEDIATES FOR THEIR PRODUCTION AND PROCESSES FOR PRODUCING THESE COMPOUNDS SUMITOMO CHEMICAL COMPANY LIMITED (JP) 1998-07-01 EP disclosed
WO-1997006150-A1 PYRIMIDIN-4-ONE DERIVATIVES, THEIR USE AS HERBICIDES, INTERMEDIATES FOR THEIR PRODUCTION AND PROCESSES FOR PRODUCING THESE COMPOUNDS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1997-02-20 WO disclosed
US-4369322-A WITH CYANOGEN CHLORIDE DEGUSSA AG (DE) 1983-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234097-A1 Compounds useful for the treatment of diseases LTC4S, CYP11B2, CYP11B1 CYP2A6 150/4885HTR2A 3843/4885TP53 3987/4885
US-12054474-B2 Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases PROKR1, GIPR, PROKR2 CYP2A6 2680/4885HTR2A 218/4885TP53 4388/4885
US-20240424110-A1 MDM2 DEGRADERS AND USES THEREOF MDM2, USP2, MYCBP2 CYP2A6 3122/4885HTR2A 2425/4885TP53 7/4885
US-12528785-B2 MDM2 degraders and uses thereof MDM2, ADRM1, RBX1 CYP2A6 781/4885HTR2A 1975/4885TP53 8/4885
US-11981664-B2 Photoresponsive nutlin derivatives and uses thereof NUTF2, DNER, TP53 CYP2A6 3456/4885HTR2A 3823/4885TP53 3/4885
US-12552783-B2 Modulators of proteolysis and associated methods of use CRBN, ADRM1, MDM2 CYP2A6 4321/4885HTR2A 3158/4885TP53 57/4885
US-20110230660-A1 METHOD FOR PREPARING A SPIROINDOLINE AND A PRECURSOR THEREOF CCR2, CXCR4, CXCR2 CYP2A6 1587/4885HTR2A 616/4885TP53 4148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.